A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine
NCT ID: NCT02784847
Last Updated: 2016-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
10 participants
INTERVENTIONAL
2016-06-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2
NCT00257985
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
NCT02122744
New Methods for Evaluating Preventive Migraine Treatment
NCT07071506
Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine
NCT01357031
Occipital Transcutaneous Stimulation in Chronic Migraine
NCT02307071
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open, non-randomized pilot trial that might justify a placebo-controlled trial, if there are at least 50% of patients with ≥50% reduction in attack frequency.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment arm
pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
Triheptanoin
Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triheptanoin
Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of migraine without aura (ICHD3beta 1.1) since at least 2 years
* 4-10 migraine days per month during the last 3 months
* No preventive anti-migraine therapy during the last month
Exclusion Criteria
* Medication overuse headache or other headache types
* Resistance to \>3 previous preventive anti-migraine drug treatments
* Any serious medical or psychiatric condition
* On-going or previous bowel disorder
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Liege
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean Schoenen
Honorary Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Schoenen, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Liège
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UX007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.